Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Core Insights - Humacyte, Inc. is a biotechnology company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3] - The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with management available for one-on-one meetings [1][2] Company Overview - Humacyte is developing a disruptive biotechnology platform aimed at improving patient lives and transforming medical practices through acellular tissues for various diseases and conditions [3] - The FDA approved Humacyte's Biologics License Application for the acellular tissue engineered vessel (ATEV) in December 2024, specifically for vascular trauma [3] - ATEVs are in late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications [3] - Humacyte's 6mm ATEV for AV access in hemodialysis received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3] - The ATEV has also received RMAT designations for urgent arterial repair following extremity vascular trauma and advanced PAD, along with priority designation for vascular trauma treatment from the U.S. Secretary of Defense [3]